PADI2 and breast carcinoma: These results not only confirmed our hypothesis that depletion or inhibiting PAD2 will partially restore the sensitivity of MCF7/TamR cells to tamoxifen, but also suggested that PAD2 is a good therapeutic candidate for tamoxifen resistant breast cancers.